Affordable Access

Publisher Website

How I treat multiple myeloma in geriatric patients.

Authors
  • Facon, Thierry1
  • Leleu, Xavier2
  • Manier, Salomon1
  • 1 Department of Hematology, University of Lille, Centre Hospitalier Universitaire Lille, Lille, France. , (France)
  • 2 Department of Hematology, University of Poitiers, Centre Hospitalier Universitaire Poitiers, Poitiers, France. , (France)
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
Jan 18, 2024
Volume
143
Issue
3
Pages
224–232
Identifiers
DOI: 10.1182/blood.2022017635
PMID: 36693134
Source
Medline
Language
English
License
Unknown

Abstract

Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric aspects in the context of MM have been poorly investigated. Treatment outcomes for geriatric patients with MM are often compromised by comorbidities and an enhanced susceptibility to adverse events from therapy. Assessment of patient frailty has become more frequent and will be useful in the context of significant and continuous advances in therapy. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immunooncology drugs, such as bispecific antibodies, will lead to additional therapeutic progress. The applicability of these new molecules to older and frail patients is a key clinical question. Here, we present 2 patient cases derived from clinical practice. We review current frailty scores and standards of care for older, newly diagnosed patients with MM, including frail subgroups, and discuss ways to tailor treatment, as well as treatment perspectives in this population. © 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Report this publication

Statistics

Seen <100 times